Dear Sirs,

After the recognition of COVID-19 disease, caused by the SARS-CoV-2, several reports refer to neurological symptoms in such patients \[[@CR1], [@CR2]\], including Guillain--Barré Syndrome (GBS) \[[@CR3]--[@CR9]\]

We describe a case of acute demyelinating polyneuritis in association with asymptomatic SARS-CoV-2 infection.

A 66-years old Maroccan woman, the resident in the Bologna area, was admitted to Imola Hospital on March 15th, 2020, for hyposthenia in all limbs, severe in lower, with a Medical Research Council (MRC) scale of 1/5 in distal and 2/5 in proximal of the lower extremities and 3/5 in distal and 4/5 in proximal of the upper extremities, with a distal tingling sensation and pronounced lumbar pain for about eight days. She was unable to walk, reported difficulty in swallowing and speeching, tendon reflexes were abolished. Vital signs were normal, medical history was negative and no infection was reported in the previous month.

We hypothesized GBS and performed nerve conduction studies consistent with demyelinating polyneuropathy (Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}) and cerebrospinal fluid (CSF) analysis, consistent with our hypothesis (protein content 245 mg/dL, cells 13/mmc, polymorphonucleate 61.5%).Table 1Antidromic sensory nerve conduction studiesAmplitude, µVConduction velocity, m/sLeft Median (digit 3-wrist)0·4 (n.v. ≥ 17)32·5 (n.v. ≥ 50)Left Ulnar (digit 5-wrist)Absent--Right Sup. Peroneal (lateral calf-lateral ankle)1·2 (n.v. ≥ 6)50·0 (n.v. ≥ 40)Righ Sural (calf-posterior ankle)1·6 (n.v. ≥ 6)58·3 (n.v. ≥ 40)Left Sural (calf-posterior ankle)1·8 (n.v. ≥ 6)48·1 (n.v. ≥ 40)Table 2Motor nerve conduction studiesDistal Latency, msAmplitude, mVConduction velocity, m/sF latency, mscMAP\
Duration, ms**Left Median** Wrist-APB9·9 (n.v ≤ 4·4)2·6 (n.v. ≥ 4·4)45·5 (n.v. ≤ 31)21.4 Antecub. fossa-wrist13·32·657·4 (n.v. ≥ 50)**Left Ulnar** Wrist-ADM6·2 (n.v. ≤ 3·3)2·5 (n.v. ≥ 6·0)41·5 (n.v. ≤ 32)33.1 Below elbow-wrist111·739·6 (n.v. ≥ 50) Ab.elbow-bel.elbow15·41·436·4**Left Tibial** Ankle-AHB12·8 (n.v. ≤ 5·8)1·8 (n.v. ≥ 4·0)Absent (n.v. ≤ 56)38.2 Popliteal fossa-ankle23·81·334·1 (n.v. ≥ 41)**Right Tibial** Ankle-AHB11·3 (n.v. ≤ 5·8)1·1 (n.v. ≥ 4.0)Absent (n.v. ≤ 56)42.7 Popliteal fossa-ankle18.91·048·7 (n.v. ≥ 41)**Left Peroneal** Ankle-EBD14·3 (n.v ≤ 0·1)0·1 (n.v ≥ 2·0)Absent (n.v. ≤ 56)30.8 Bel.fibula-ankle22·80·430·6 (n.v. ≥ 41) Ab.fibula-bel.fibula26·10·530·3**Right Peroneal** Ankle-EBD7·4 (n.v ≤ 0·1)3·0 (n.v. ≥ 2·0)Absent (n.v. ≤ 56)19.8 Bel.fibula-ankle161·830·2 (n.v. ≥ 41) Ab.fibula-bel.fibula19·1·828·9Distal compound muscle action potentials (cMAP) showed reduced amplitude because of temporal dispersion due to demyelination*APB* abductor pollicis brevis, *ADM* abductor digiti minimi, *AHB* abductor hallucis brevis, *EBD* extensor digitorum brevis, *n.v.* normal value

Microbiologic testing on CSF and serum was negative (HSV1-2, EBV, VZV, CMV, HIV, Mycoplasma Pneumoniae, Borrelia). Anti-ganglioside antibodies were negative. We excluded electrolytic abnormalities, heavy metal or drugs toxicity, endocrinological disorders, folate and vitamin B12 deficiency.

Blood analysis showed elevated CPK (461 U/L, normal \< 145), CRP (5·65 mg/dL, normal \< 0·5), lymphocytopenia (0·68 × 10^9^/L, normal 1·10--4), mild increase of LDH (284 U/L, normal \< 248), GOT and GPT (549 and 547 U/L, normal \< 35), similarly to COVID-19 patients laboratory profile \[[@CR10]\].

Thus, considering the rapid spread of this infection in our region and its pandemic extent, we decided to perform a RT-PCR for SARS-CoV-2 on nasopharyngeal swab, which resulted positive.

We found elevation of Interleukin 6 (11 pg/mL, normal \< 5·9), also associated with Covid-19 disease \[[@CR10]\]. She was transferred to Covid-19 department and received a five days course of intravenous immune globulin (IvIg), ritonavir 100 mg and darunavir 800 mg per day with hydroxychloroquine 200 mg twice daily, according to our hospital protocol for COVID-19 treatment. She never developed respiratory symptoms or fever; thoracic CT scan was normal.

Immediately after IvIg, she significantly improved with a MRC scale of 4/5 in distal of upper limbs and 3/5 both proximal and distal in lower limbs, while facial diplegia has developed.

About 3 weeks after the onset of neurological symptoms two nasopharyngeal swabs, 24 hours apart, resulted negative and she was transferred to rehabilitation care.

To our knowledge, this is the first case of GBS in patient with asymptomatic COVID-19 and laboratory tests consistent with SARS-COV-2 infection. We think the infection wasn't nosocomial, although we cannot absolutely exclude it, because the swab was performed within twelve hours from hospitalization and isolation protocols of suspected patients had been applied. Patient's relatives did not develop symptoms but were observed in isolation for 2 weeks.

The association between COVID-19 and GBS has recently been described both as parainfectious \[[@CR3], [@CR7], [@CR8]\] and as post-infective event \[[@CR4], [@CR5], [@CR9]\], similar to other infections and coronavirus \[[@CR11], [@CR12]\], suggesting a mechanism of molecular mimicry or part of systemic inflammatory cascade triggered by the virus. Facial diplegia seems recurrent in GBS related to COVID-19 \[[@CR7], [@CR8]\].

Interesting in our case a patient asymptomatic for COVID-19 develops neurological impairment as a unique clinical event, probably as part of dysimmune process.

Unfortunately, we could not perform a serological test or CSF PCR for COVID-19.

We believe this association may not be a coincidence, more cases could be evaluated, possibly supported by serological and CSF tests, and underlines the importance of looking for neurological impairment in COVID-19 disease and address the correct treatment, such as IvIg, also for respiratory function worsening independently from pneumonitis.
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